176 related articles for article (PubMed ID: 18203652)
1. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma.
Riechelmann H; Sauter A; Golze W; Hanft G; Schroen C; Hoermann K; Erhardt T; Gronau S
Oral Oncol; 2008 Sep; 44(9):823-9. PubMed ID: 18203652
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
Sauter A; Kloft C; Gronau S; Bogeschdorfer F; Erhardt T; Golze W; Schroen C; Staab A; Riechelmann H; Hoermann K
Int J Oncol; 2007 Apr; 30(4):927-35. PubMed ID: 17332932
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
Rupp U; Schoendorf-Holland E; Eichbaum M; Schuetz F; Lauschner I; Schmidt P; Staab A; Hanft G; Huober J; Sinn HP; Sohn C; Schneeweiss A
Anticancer Drugs; 2007 Apr; 18(4):477-85. PubMed ID: 17351401
[TBL] [Abstract][Full Text] [Related]
5. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo.
Gurtner K; Hessel F; Eicheler W; Dörfler A; Zips D; Heider KH; Krause M; Baumann M
Radiother Oncol; 2012 Mar; 102(3):444-9. PubMed ID: 22100655
[TBL] [Abstract][Full Text] [Related]
7. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
10. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
Tolcher AW; Ochoa L; Hammond LA; Patnaik A; Edwards T; Takimoto C; Smith L; de Bono J; Schwartz G; Mays T; Jonak ZL; Johnson R; DeWitte M; Martino H; Audette C; Maes K; Chari RV; Lambert JM; Rowinsky EK
J Clin Oncol; 2003 Jan; 21(2):211-22. PubMed ID: 12525512
[TBL] [Abstract][Full Text] [Related]
11. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
12. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
Rodon J; Garrison M; Hammond LA; de Bono J; Smith L; Forero L; Hao D; Takimoto C; Lambert JM; Pandite L; Howard M; Xie H; Tolcher AW
Cancer Chemother Pharmacol; 2008 Oct; 62(5):911-9. PubMed ID: 18301896
[TBL] [Abstract][Full Text] [Related]
13. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Roos JC; de Bree R; Wilhelm AJ; Kummer JA; Hanft G; Heider KH; Stehle G; Snow GB; van Dongen GA
Cancer Immunol Immunother; 2003 Sep; 52(9):576-82. PubMed ID: 14627130
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Helft PR; Schilsky RL; Hoke FJ; Williams D; Kindler HL; Sprague E; DeWitte M; Martino HK; Erickson J; Pandite L; Russo M; Lambert JM; Howard M; Ratain MJ
Clin Cancer Res; 2004 Jul; 10(13):4363-8. PubMed ID: 15240523
[TBL] [Abstract][Full Text] [Related]
15. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
Shah MH; Lorigan P; O'Brien ME; Fossella FV; Moore KN; Bhatia S; Kirby M; Woll PJ
Invest New Drugs; 2016 Jun; 34(3):290-9. PubMed ID: 26961907
[TBL] [Abstract][Full Text] [Related]
17. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
Liebisch P; Eppinger S; Schöpflin C; Stehle G; Munzert G; Döhner H; Schmid M
Haematologica; 2005 Apr; 90(4):489-93. PubMed ID: 15820944
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinical characterization of an 111In-labeled monoclonal antibody.
Sandström K; Nestor M; Ekberg T; Engström M; Anniko M; Lundqvist H
Tumour Biol; 2008; 29(3):137-44. PubMed ID: 18612218
[TBL] [Abstract][Full Text] [Related]
19. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
[TBL] [Abstract][Full Text] [Related]
20. CD44s and CD44v6 expression in head and neck epithelia.
Mack B; Gires O
PLoS One; 2008; 3(10):e3360. PubMed ID: 18852874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
